Navigation Links
TorreyPines Therapeutics Sells Alzheimer's Disease Genetics Program to Eisai
Date:11/10/2008

LA JOLLA, Calif., Nov. 10 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has agreed to sell its Alzheimer's disease genetics research program to Eisai Co., Ltd. for an upfront cash payment. TorreyPines and Eisai have collaborated on the genetics program since 2002, with the most recent agreement between the parties concluding on September 30, 2008. The Alzheimer's disease genetics research program focused on the discovery of Alzheimer's disease targets using whole-genome family-based association screening.

"We are pleased to announce the sale of our genetics program to our long-time partner, Eisai," said Ev Graham, acting chief executive officer of TorreyPines Therapeutics. "The sale of this asset furthers our transition to a development-only company and enables us to focus our resources on advancing our clinical stage assets: tezampanel, NGX426 and NGX267. As a leader in treating Alzheimer's disease we believe Eisai is well positioned to capitalize on the discoveries from the genetics program."

The genetics program is one of two TorreyPines discovery programs focused on Alzheimer's disease, the other being a gamma secretase modulator (GSM) program. Recently, a lead compound from the GSM program has been shown to reduce plaque load and Abeta peptide levels in the brains of Tg2576 Alzheimer's disease model mice after seven months of oral dosing. TorreyPines is currently seeking a partner for this program.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's go
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Global Stem Cells Group.com has ... Bioengineering Co., Ltd. and its Chinese-American founder Mingjie ... stem cells training course in the City of ... Shenzhen HANK is a biotechnology company established in ... virologist, to integrate research, development, production, and sales ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine Inc. ... aware of a fraudulent press release disseminated this morning ... be from Immunovaccine. This press release states that Immunovaccine ... Inc. The press release did not originate from ... contained within the press release. Please note that ...
(Date:2/27/2015)... Feb. 27, 2015 Research and Markets ( ... Market Report of Trypsin" report to their offering. ... aims at providing comprehensive data on Trypsin globally and regionally ... North America , Latin America ... attention to Trypsin This report focuses on three ...
(Date:2/27/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... announced that it will be presenting at CALBIO 2015 ... nd at 3pm PST. Patrick Lucy, chief business officer ... current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and The ...
Breaking Biology Technology:Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3Immunovaccine Disclaims Hoax Press Release 2Global Market Report of Trypsin 2014-2018 2
... Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Pharmaceuticals, ... Lidocaine Sponge for the management of painful wounds. ... worldwide suffer from chronic wounds (venous stasis ulcers, pressure ... all chronic wounds do not heal within 5 years. ...
... that since few people can afford to travel outside the country ... ultra safe adult stem cell treatments to alleviate the suffering of ... ... Thailand (PRWEB) March 31, 2009 -- Don Margolis, founder of the ...
... and MOUNTAIN VIEW, Calif., March 31 ... agreement to supply high quality services and oligonucleotides to ... the terms of the agreement, Sigma-Aldrich will be the ... the two Companies will engage in co-marketing efforts to ...
Cached Biology Technology:Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge 2Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research 2Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research 3Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 2Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 3
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , a ... today announced that Murali Prahalad , Ph.D., president and ... World Conference (PMWC) 2015: Silicon Valley, which is taking ... View, Calif. on January 26-28, 2015. ... of Age as Biomarkers." Last year, Epic Sciences was a ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... the upcoming RedChip Global Online CEO Conference on January ... Gino Pereira , CEO of NXT-ID will ... lead product, the Wocket smart wallet and its full ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the ... report to their offering. , The ... individual is who she/he is claiming to be, and for ... unique physical characteristics, such as fingerprint, hand or palm print, ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... a jar of alcohol in The Natural History Museum , London ... of the least known bat species on the planet, for over 140 ... Dr. Don Buden from the College of Micronesia has collected ... for the first time. The study is reported today in the open ...
... 50th anniversary celebrations, Clemson,s bioengineering department is ... the 2013 Clemson Biomaterials Symposium, Biomaterials-What,s Next, ... Biomaterials research is an interdisciplinary science, comprising ... science, with deep roots at Clemson University. ...
... from the University of York, has shed important new ... at the nanoscale, provide valuable new information for scientists ... the threats of acidification and rising water temperatures., As ... skeletons which build up over time into vast reefs. ...
Cached Biology News:Old bat gets a new name 2Clemson hosting biomaterials symposium 2Physicists provide new insights into coral skeleton formation 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
Experion StdSens chips are the microfluidic chips used to perform standard-sensitivity RNA analysis (nanogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to...
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
Biology Products: